

# Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: a systematic review and meta-analysis of randomised trials

Annals of the Rheumatic Diseases

72, 1696-1699

DOI: [10.1136/annrheumdis-2012-202836](https://doi.org/10.1136/annrheumdis-2012-202836)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Complex Raynaudâ€™s phenomenon: evolving concepts of management. International Journal of Clinical Rheumatology, 2013, 8, 689-706.	0.3	0
2	Erectile dysfunction medication induced-changes in plasma levels of homocysteine and antioxidant enzyme activities as risk factors for cardiovascular disease. Journal of Taibah University Medical Sciences, 2013, 8, 151-156.	0.9	2
3	Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential. Journal of Receptor, Ligand and Channel Research, 0, , 19.	0.7	10
4	Redox Signaling as a Therapeutic Target to Inhibit Myofibroblast Activation in Degenerative Fibrotic Disease. BioMed Research International, 2014, 2014, 1-14.	1.9	46
5	Treatment options in Raynaud's phenomenon. Expert Opinion on Orphan Drugs, 2014, 2, 271-282.	0.8	0
6	Raynaud Syndrome. Techniques in Vascular and Interventional Radiology, 2014, 17, 241-246.	1.0	17
8	Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2H)-one as a phosphodiesterase-5 inhibitor and its complex crystal structure. Biochemical Pharmacology, 2014, 89, 86-98.	4.4	25
9	Effects of phosphodiesterase type 5 inhibitors on Raynaudâ€™s phenomenon. Rheumatology International, 2014, 34, 1623-1626.	3.0	9
11	Recognizing and treating Raynaud phenomenon. JAAPA: Official Journal of the American Academy of Physician Assistants, 2015, 28, 40-44.	0.3	4
12	Optimal management of digital ulcers in systemic sclerosis. Therapeutics and Clinical Risk Management, 2015, 11, 939.	2.0	26
14	Drug Treatment of Raynaudâ€™s Phenomenon. , 2015, , 315-337.		0
15	Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma. Rheumatic Disease Clinics of North America, 2015, 41, 419-438.	1.9	37
16	Systemic sclerosis: Recent insights. Joint Bone Spine, 2015, 82, 148-153.	1.6	54
17	Erectile dysfunction drugs and oxidative stress in the liver of male rats. Toxicology Reports, 2015, 2, 933-938.	3.3	27
18	Consensus best practice pathway of the UK Scleroderma Study Group: digital vasculopathy in systemic sclerosis. Rheumatology, 2015, 54, 2015-2024.	1.9	108
19	Macro- and microvascular disease in systemic sclerosis. Vascular Pharmacology, 2015, 71, 16-23.	2.1	29
20	Management of Raynaudâ€™s Phenomenon and Digital Ulcers. Current Treatment Options in Rheumatology, 2015, 1, 68-81.	1.4	4
21	Systemic sclerosis. Current Opinion in Rheumatology, 2015, 27, 241-248.	4.3	32

#	ARTICLE	IF	CITATIONS
22	Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2015, 21, 149-155.	0.9	14
24	Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient. <i>Reumatismo</i> , 2016, 68, 109-111.	0.9	3
25	Recent advances in the pathogenesis and management of Raynaud's phenomenon and digital ulcers. <i>Current Opinion in Rheumatology</i> , 2016, 28, 577-585.	4.3	26
26	Raynaud's phenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 112-132.	3.3	78
27	A New Proposal for Management of Severe Frostbite in the Austere Environment. <i>Wilderness and Environmental Medicine</i> , 2016, 27, 92-99.	0.9	56
29	Raynaud's Phenomenon. <i>New England Journal of Medicine</i> , 2016, 375, 556-565.	27.0	233
30	Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. <i>Annals of Pharmacotherapy</i> , 2016, 50, 1060-1067.	1.9	17
31	Sildenafil (Viagra®) prevents and restores LPS-induced inflammation in astrocytes. <i>Neuroscience Letters</i> , 2016, 630, 59-65.	2.1	19
32	Early morphologic and functional changes of atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2016, 55, 2119-2130.	1.9	28
33	Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 252-269.	1.4	53
34	Erectile Dysfunction in Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2016, 18, 49.	4.7	12
36	Raynaud Phenomenon and Vasomotor Syndromes. , 2016, , 436-447.e3.		1
37	Systemic Sclerodermas. , 2016, , 384-405.e9.		1
38	Systemic sclerosis: An update in 2016. <i>Autoimmunity Reviews</i> , 2016, 15, 417-426.	5.8	126
39	Combination therapy with Bosentan and Sildenafil improves Raynaud's phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. <i>Clinical Rheumatology</i> , 2016, 35, 127-132.	2.2	24
40	Vasoactive Therapy in Systemic Sclerosis: Real-life Therapeutic Practice in More Than 3000 Patients. <i>Journal of Rheumatology</i> , 2016, 43, 66-74.	2.0	42
41	Therapeutic implications from the pathogenesis of Raynaud's phenomenon. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 723-735.	3.0	8
42	Algoritmo terapéutico del fenómeno de Raynaud y de las ulceraciones digitales isquémicas de la esclerodermia sistémica. <i>Piel</i> , 2017, 32, 363-368.	0.0	1

#	ARTICLE	IF	CITATIONS
43	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
44	How I treat patients with systemic sclerosis in clinical practice. <i>Autoimmunity Reviews</i> , 2017, 16, 1024-1028.	5.8	20
45	Assessment and management of Raynaud's phenomenon. <i>The Prescriber</i> , 2017, 28, 11-16.	0.3	3
46	European Dermatology Forum S1 guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1401-1424.	2.4	148
47	Evidence-based management of Raynaud's phenomenon. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 317-329.	2.7	21
48	Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2370-2379.	5.6	49
49	The Role of NO/cGMP Signaling on Neuroinflammation: A New Therapeutic Opportunity. , 2017, , .		6
50	Phosphodiesterase type 5 and cancers: progress and challenges. <i>Oncotarget</i> , 2017, 8, 99179-99202.	1.8	42
51	Raynaud's phenomenon: Current concepts. <i>Clinics in Dermatology</i> , 2018, 36, 498-507.	1.6	30
52	A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1110-1118.e3.	1.2	28
53	Systemic sclerosis: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , 2018, 36, 459-474.	1.6	43
54	Advances in Upper Extremity Scleroderma Wound Care. <i>Advances in Skin and Wound Care</i> , 2018, 31, 446-455.	1.0	1
55	Raynaud's Phenomenon. , 2018, , .		0
56	On-Demand Sildenafil as a Treatment for Raynaud Phenomenon. <i>Annals of Internal Medicine</i> , 2018, 169, 694.	3.9	26
57	Use of nitroglycerin ointment to treat primary and secondary Raynaud's phenomenon: a systematic literature review. <i>Rheumatology International</i> , 2018, 38, 2209-2216.	3.0	13
59	The contemporary management of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 573-582.	3.0	2
60	The Scleroderma Hand: Manifestations of Disease and Approach to Management. <i>Journal of Hand Surgery</i> , 2018, 43, 550-557.	1.6	14
61	Sildenafil Therapy in Patients With Digital Burns and Raynaud's Syndrome. <i>Journal of Burn Care and Research</i> , 2019, 40, 136-139.	0.4	2

#	ARTICLE	IF	CITATIONS
62	The clinical effects of L-arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 497-503.	2.4	13
64	Raynaud's phenomenon: an update on diagnosis, classification and management. <i>Clinical Rheumatology</i> , 2019, 38, 3317-3330.	2.2	67
65	Morphea and Scleroderma. , 2019, , 989-1002.		0
67	Management of Raynaud's phenomenon in systemic sclerosis: a practical approach. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 102-110.	1.7	9
69	Aminaphtone Efficacy in Primary and Secondary Raynaud's Phenomenon: A Feasibility Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 293.	3.5	10
70	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 85-103.	1.4	8
71	Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 89-101.	1.7	18
72	Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials. <i>Lancet Rheumatology</i> , The, 2019, 1, e237-e246.	3.9	18
73	Systemic sclerosis. , 2019, , 291-329.		0
74	Tadalafil: 15 years' journey in male erectile dysfunction and beyond. <i>Drug Development Research</i> , 2019, 80, 683-701.	2.9	16
75	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 18-26.	1.9	37
76	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. <i>British Journal of Pharmacology</i> , 2020, 177, 5467-5488.	5.4	65
77	Online LC-QTOF-MS micro-fractionation of <i>Derris scandens</i> (Roxb.) Benth, coupled to radioassay for the early identification of PDE5A1 inhibitors. <i>Phytochemical Analysis</i> , 2020, 31, 297-305.	2.4	5
78	Patient-reported outcome instruments in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 90-102.	1.7	14
79	Systemic sclerosis: Update for oral health care providers. <i>Special Care in Dentistry</i> , 2020, 40, 418-430.	0.8	5
80	An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2041-2056.	1.8	15
81	Álceras digitales en esclerosis sistémica. <i>Revista Colombiana De Reumatología</i> , 2020, 27, 26-35.	0.1	0
83	Drug Treatment of Raynaud's Phenomenon of the Nipple. <i>Breastfeeding Medicine</i> , 2020, 15, 686-688.	1.7	6

#	ARTICLE	IF	CITATIONS
84	Scleroderma of the Hand: Evaluation and Treatment. Journal of the American Academy of Orthopaedic Surgeons, The, 2020, 28, e686-e695.	2.5	8
85	Infections and systemic sclerosis: an emerging challenge. Revista Colombiana De ReumatologÃa (English Edition), 2020, 27, 62-84.	0.0	1
86	Digital ulcers in systemic sclerosis. Revista Colombiana De ReumatologÃa (English Edition), 2020, 27, 26-35.	0.0	0
87	Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets. Autoimmunity Reviews, 2020, 19, 102583.	5.8	25
88	Raynaud's phenomenon. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101474.	3.3	43
90	Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2022, 62, 273-291.	6.5	28
91	Raynaudâ€™s phenomenon and related vasospastic disorders. Vascular Medicine, 2021, 26, 56-70.	1.5	17
92	Raynaudâ€™s Phenomenon: A Vascular Acrosyndrome That Requires Long-Term Care. Deutsches A&#x0308;rzteblatt International, 2021, 118, .	0.9	8
93	Emerging treatments for scleroderma/systemic sclerosis. Faculty Reviews, 2021, 10, 43.	3.9	11
94	Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis. American Journal of Physical Medicine and Rehabilitation, 2022, 101, 341-347.	1.4	0
95	The Effects of Botulinum Toxin A on Pain in Ischemic Vasospasm. Journal of Hand Surgery, 2021, 46, 513.e1-513.e12.	1.6	5
96	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part III: Pharmacology, medical and surgical management of post-transplant extrapulmonary conditions statements. Journal of Heart and Lung Transplantation, 2021, 40, 1279-1300.	0.6	3
97	Raynaudâ€™s Secondary to Granulomatosis With Polyangiitis. Cureus, 2021, 13, e17551.	0.5	0
98	Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia. Acta Obstetrica Et Gynecologica Scandinavica, 2021, 100, 2111-2118.	2.8	2
99	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. Rheumatic Disease Clinics of North America, 2021, 47, 757-780.	1.9	5
101	Improvement of peripheral artery disease with Sildenafil and Bosentan combined therapy in a patient with limited cutaneous systemic sclerosis. Medicine (United States), 2017, 96, e6988.	1.0	7
102	ADVANCES IN THERAPIES FOR SYSTEMIC SCLEROSIS. , 2015, , 165-198.		1
103	Treating Raynaud phenomenon: Beyond staying warm. Cleveland Clinic Journal of Medicine, 2017, 84, 797-804.	1.3	7

#	ARTICLE	IF	CITATIONS
104	Phosphodiesterase-5 inhibitors: Raynaud's and beyond. Indian Journal of Rheumatology, 2017, 12, 227.	0.4	1
105	In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks. Annals of Internal Medicine, 2019, 170, JC21.	3.9	3
106	Raynaud Phenomenon and Other Vasospastic Disorders. Cardiology Clinics, 2021, 39, 583-599.	2.2	5
107	Secondary Raynaudâ€™s Phenomenon. , 2015, , 107-127.		0
108	Historical Perspective of Raynaudâ€™s Phenomenon. , 2015, , 1-11.		1
109	Raynaud phenomenon. , 2015, , 1213-1218.		0
110	Scleroderma: Not an orphan disease any more. World Journal of Rheumatology, 2015, 5, 131.	0.5	1
111	Raynaudâ€™s Phenomenon, Digital Ulcers and Nailfold Capillaroscopy. , 2017, , 297-316.		1
113	Raynaudâ€™s Phenomenon and Ulcers. , 2019, , 45-62.		0
115	Male Sexual Dysfunction in Systemic Sclerosis. In Clinical Practice, 2021, , 299-305.	0.0	0
116	Raynaudâ€™s Phenomenon. In Clinical Practice, 2021, , 67-77.	0.0	0
118	Effect of Losartan in Complete Freund's Adjuvant -Induced Arthritis in Rats. Iranian Journal of Pharmaceutical Research, 2018, 17, 1420-1430.	0.5	7
119	Systemic sclerosis in adults. Part II: management and therapeutics. Journal of the American Academy of Dermatology, 2022, 87, 957-978.	1.2	7
120	Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies. Frontiers in Medicine, 2021, 8, 788250.	2.6	25
121	Raynaudâ€™s Phenomenon with Focus on Systemic Sclerosis. Journal of Clinical Medicine, 2022, 11, 2490.	2.4	8
123	Practical management of Raynaud's phenomenon â€“ a primer for practicing physicians. Current Opinion in Rheumatology, 2022, 34, 235-244.	4.3	2
124	Treatment of resistant Raynaud's phenomenon with single-port thoracoscopic sympathectomy: One-year follow-up. Seminars in Arthritis and Rheumatism, 2022, 56, 152065.	3.4	0
125	Part II: The treatment of primary and secondary Raynaud's phenomenon. Journal of the American Academy of Dermatology, 2024, 90, 237-248.	1.2	1

#	ARTICLE	IF	CITATIONS
127	Assessment of the Systemic Sclerosis-Associated Raynaud's Phenomenon Questionnaire: Item Bank and Short-Form Development. <i>Arthritis Care and Research</i> , 2023, 75, 1725-1734.	3.4	6
128	Application of Modern Analytical Techniques for quantification of Tadalafil in Pharmaceutical and Biological Matrices: Future Prospectus.. <i>Current Pharmaceutical Analysis</i> , 2022, 19, .	0.6	0
129	Clinical Overview of Inflammatory Dermatologic Conditions. , 2022, , 341-344.		0
130	Advances in the Treatment of Systemic Sclerosis. , 2022, 1, 61.		0
132	Managing cold intolerance after hand injury: A systematic review. <i>Hand Surgery and Rehabilitation</i> , 2023, 42, 109-114.	0.4	1
133	State-of-the-art evidence in the treatment of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2023, 19, 212-226.	8.0	21
134	Raynaud's phenomenon: A brush up!. <i>Indian Dermatology Online Journal</i> , 2023, 14, 248.	0.5	1
135	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon. , 2023, , 111-132.		0
136	Cold Hands or Feet. <i>Medical Clinics of North America</i> , 2023, 107, 829-844.	2.5	1
137	Pharmacological management of digital ulcers in systemic sclerosis - what is new?. <i>Expert Opinion on Pharmacotherapy</i> , 2023, 24, 1159-1170.	1.8	0
138	Construct validity and reliability of the Assessment of Systemic Sclerosis-Associated Raynaud's Phenomenon (ASRAP) questionnaire. <i>Rheumatology</i> , 0, .	1.9	1
140	Systemic sclerosis sine scleroderma with atypical clinical course: a rare case report. <i>Annals of Medicine and Surgery</i> , 2023, 85, 5656-5661.	1.1	1
141	Efficacy analysis of minimally invasive surgery for Raynaud's syndrome. <i>BMC Surgery</i> , 2023, 23, .	1.3	1
142	Phosphodiesterase 5 inhibitors (PDE5i) for the treatment of Raynaud's phenomenon. <i>The Cochrane Library</i> , 2023, 2023, .	2.8	0
143	Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022. <i>Expert Review of Clinical Immunology</i> , 0, , 1-18.	3.0	0
144	Princeton IV consensus guidelines: PDE5 inhibitors and cardiac health. <i>Journal of Sexual Medicine</i> , 2024, 21, 90-116.	0.6	0
145	Medium- and Long-Term Outcomes of Autologous Fat Grafting to Hands and Feet for Patients With Raynaud Phenomenon. <i>Annals of Plastic Surgery</i> , 2024, 92, 287-293.	0.9	0
146	Sekundäres Raynaud-Phänomen. <i>Springer Reference Medizin</i> , 2024, , 1-9.	0.0	0



#	ARTICLE	IF	CITATIONS
147	Consensus statement on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: Localized scleroderma, systemic sclerosis and overlap syndromes. Journal of the European Academy of Dermatology and Venereology, 0, , .	2.4	0